|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
18 years and older
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:clinicalTrialsGovURL
|
https://clinicaltrials.gov/ct2/show/NCT02477826
|
|
gptkbp:conditionStudied
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:enrollment
|
1274
|
|
gptkbp:gender
|
All
|
|
gptkbp:intervention
|
gptkb:Placebo
gptkb:Pembrolizumab
|
|
gptkbp:location
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:officialName
|
A Phase 3 Study of Pembrolizumab (MK-3475) as Adjuvant Therapy in Participants With Resected Stage IB (T ≥4 cm), II or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-091)
|
|
gptkbp:primaryCompletionDate
|
September 2022
|
|
gptkbp:primaryOutcomeMeasure
|
Disease-Free Survival (DFS)
|
|
gptkbp:recognizedBy
|
KEYNOTE-091
|
|
gptkbp:secondaryOutcomeMeasure
|
Overall Survival (OS)
|
|
gptkbp:sponsor
|
gptkb:Merck_Sharp_&_Dohme_LLC
|
|
gptkbp:startDate
|
June 2015
|
|
gptkbp:status
|
Completed
|
|
gptkbp:studyType
|
Interventional
|
|
gptkbp:bfsParent
|
gptkb:CheckMate_227
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NCT02477826
|